Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome

Core Viewpoint - Acadia Pharmaceuticals Inc. has received FDA approval for DAYBUE® STIX (trofinetide), a new oral solution formulation for treating Rett syndrome in patients aged two years and older [1] Group 1: Product Details - DAYBUE® STIX is a dye- and preservative-free powder formulation of trofinetide [1] - The new formulation is expected to maintain the same efficacy and safety profile as the existing DAYBUE oral solution [1] Group 2: Target Patient Population - The approved treatment is intended for both adult and pediatric patients aged two years and older suffering from Rett syndrome [1]